




TTY Biopharm 4105

Operational Results Report



2024.08.28

Disclaimer

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

- 1 pricing and product initiatives of competitors;
- 2 legislative and regulatory developments and economic conditions;
- 3 delay or inability in obtaining regulatory approvals or bringing products to market;
- 4 fluctuations in currency exchange rates and general financial market conditions;
- 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
- 6 increased government pricing pressures;
- 7 interruptions in production
- 8 loss of or inability to obtain adequate protection for intellectual property rights;
- 9 litigation;
- 10 loss of key executives or other employees; and
- 11 adverse publicity and news coverage.

TTY Biopharm cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. TTY Biopharm undertakes no obligation to update publicly or revise any forward-looking statements. Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that TTY Biopharm's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of TTY Biopharm Company Limited.

01 Q2/2024 Operational Highlights



Strong Revenue with Overseas Market Expansion

Operational
Results Report

Revenue Overview

√ YoY Consolidated Revenue
+9% (2.65 billion)

√ Consolidated Operating
Gross Margin **60%**

√ EPS remained app. the same
as same period last year **2.2**

Market Development Highlights

- Received milestone from European and overseas market respectively from co-developed products of long-lasting microsphere and liposomes drugs with international pharma companies.
- To explore the Vietnamese market by signing memorandums with 4 Vietnamese hospitals to provide multiple treatment options for cancers.


1H/2024
Operational
Highlights

1H/2024
Financial
Performance

2024 Outlook


Sales of Oncology

(Unit: NT Mn)



Sales of Antibiotics

(Unit: NT Mn)



Three Arrows of Operation with Outstanding Results

Export the Difficulty Generic Drugs

- Received milestone from overseas market of long-lasting microsphere drug, OT2015.
- Received milestone from European market of liposome products, Amphotericin B, Lipo-AB.

Self-developed New Drug

- Polymyxin B, the antibiotics new drug received license.

License-in the International New Drugs

- The "cocktail therapy" with oral chemotherapy drugs and monoclonal antibody-targeted drugs for metastatic colorectal cancer has been approved by the TFDA.
- The 5-Fu, compound oral capsule cancer drug, TS-1, has a new indication for early breast cancer and received certification on August 22, 2024.
- The cellular influenza vaccine distributing by TTY was published in an authoritative journal on the latest protective effect.

Product Pipeline: Self-develop, License-in, Cooperation

Operational
Results Report

1H/2024
Operational
Highlights

1H/2024
Financial
Performance

2024 Outlook

- Alliance with international partners to strengthen the advantage of the product portfolio
- Joint-develop specialty of generic drugs with international partners and expand overseas markets

Oncology	2024	2025	2026
TTY_2P (MM)	→		
TTY_F (Breast Cancer)	→		
TTY_A (Lung Cancer NSCLC)	→		
TTY_B (Lymphoma)	→		

Intensive Care	2024	2025	2026
TTY_6 (Limited to serious infections of gram-negative bacteria that are ineffective against general antibiotics and have multi-drug resistance)	→		
TTY_2D (Skin tissue infections and bacteremia caused by Gram-positive bacteria)	→		
TTY_3T	→		
TTY_3D	→		
Vaccine	2024	2025	2026
TTY_B Vaccine	→		
Specialty	2024	2025	2026
Lipo-AB (liposomes): EU	→		
OT2015 (Microspheres): US	→		

• Note: those without marked are in Taiwan

Deploy Globally and Expand Overseas Market


Operational
Results Report

1H/2024
Operational
Highlights

1H/2024
Financial
Performance

2024 Outlook

- License-in/ collaboration/ **sales 130 drugs in 18 countries globally.**
- The export market will continue to grow and expand steadily, focusing on the development of the US and other major markets.
- Deepen cooperation with ASEAN markets, and sign MOUs with key hospitals in Vietnam market.



02 1H/2024 Financial Performance



1H/2024 Financial Performance

Operational Results Report

1H/2024
Operational
Highlights

1H/2024
Financial
Performance

2024 Outlook

Income Statement

(Unit: NT Thousand,
except EPS)

	1H/2024	1H/2023	YoY %
Net Sales	2,648,256	2,427,895	+9%
Operating Cost	(1,067,617)	(958,067)	+11%
Gross Profit	1,580,639	1,469,828	+8%
Gross Margin (%)	60%	61%	
Operating Expenses	(988,540)	(887,765)	+11%
Operating Profit	592,792	579,382	+2%
Operating Margin (%)	23%	24%	
Non-operating Income	124,778	107,348	+16%
Profit before Tax	717,570	686,730	+4%
Net Income (Consolidated)	566,703	546,336	+4%
Net Margin (%)	22%	23%	
EPS (Unit : NTD)	2.2	2.2	

1H/2024 Financial Performance

- YoY consolidated revenue +9% due to the royalty income, high growth of overseas markets in US and Korea, and momentum of reinvestment.
- YoY consolidated operating gross profit at 60% (-1%) due to the impact of product portfolio.
- Operating profit increased 11% than last year same period by the increased of R&D fee.
- Non-operating income increased by 16% due to the increase in profits recognized by the equity method of 13.84 million.
- Net income after tax was 567 million, an increase of 4%. 1H/2024 EPS NTD\$2.2 was about the same as the same period last year.
- The net profit attributable to owners of the parent company in 1H/2024 was 542 million.

1H/2024 Steady Revenue Growth

Operational
Results Report


1H/2024 Revenue Breakdown 1H/2024 Revenue Growth

1H/2024
Operational
Highlights


**1H/2024
Financial
Performance**

2024 Outlook

Product Category %



Revenue (NT Mn)



1H/2024
Operational
Highlights


1H/2024
Financial
Performance

2024 Outlook

03 2024 Outlook




Core Strategy and the Three Arrows are Implemented




Strengthen Global Deployment

Explore potential products and expand international market through authorization, distribution, strategic cooperation and M&A.




International Regulations

Understand the regulations in targeted markets and plan for the RA strategy and timeline to speed-up products launch.




R&D Potentials

Integrate key technologies to create and focus on specialty platforms (liposomes, microspheres) to speed-up product development.



Optimize Manufacturing Processes

Construct and maintain PIC/S GMP management system to manufacture injection and oral drugs.



Expand Marketing and Sales Channels

Expand domestic and overseas channels to promote high quality and suitable pharmaceutical drugs, to fulfill the unmet needs of patients and market.